News BridgeBio poised to challenge Pfizer after Attruby approval BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer
News Pfizer claims FDA okay for rare heart disease drug tafamidis The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyr
News Pfizer set for July FDA verdict on rare heart disease drug Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe.
News Pfizer drug reduces mortality in patients with fatal heart d... Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.